Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings

Szczegóły
Opis

Tytuł:: Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings
Autorzy:: Sasisopin Kiertiburanakul
David Boettiger
Oon Tek Ng
Nguyen Van Kinh
Tuti Parwati Merati
Anchalee Avihingsanon
Wing-Wai Wong
Man Po Lee
Romanee Chaiwarith
Adeeba Kamarulzaman
Pacharee Kantipong
Fujie Zhang
Jun Yong Choi
Nagalingeswaran Kumarasamy
Rossana Ditangco
Do Duy Cuong
Shinichi Oka
Benedict Lim Heng Sim
Winai Ratanasuwan
Penh Sun Ly
Evy Yunihastuti
Sanjay Pujari
Jeremy L. Ross
Matthew Law
Somnuek Sungkanuparph
on behalf of the TREAT Asia HIV Observational Databases (TAHOD)
Temat:: Abacavir
HIV RNA
Model
Prediction
Rilpivirine
Immunologic diseases. Allergy
RC581-607
Źródło:: AIDS Research and Therapy, Vol 14, Iss 1, Pp 1-8 (2017)
Wydawca:: BMC, 2017.
Rok publikacji:: 2017
Kolekcja:: LCC:Immunologic diseases. Allergy
Typ dokumentu:: article
Opis pliku:: electronic resource
Język:: English
ISSN:: 1742-6405
Relacje:: http://link.springer.com/article/10.1186/s12981-017-0151-1; https://doaj.org/toc/1742-6405
DOI:: 10.1186/s12981-017-0151-1
Dostęp URL:: https://doaj.org/article/0f687c31cd6545d8ab9081cd198bdf01 Link otwiera się w nowym oknie
Numer akcesji:: edsdoj.0f687c31cd6545d8ab9081cd198bdf01
: Czasopismo naukowe

Pełny tekst

Abstract Background Abacavir and rilpivirine are alternative antiretroviral drugs for treatment-naïve HIV-infected patients. However, both drugs are only recommended for the patients who have pre-treatment HIV RNA 30 kg/m2 (OR 2.4 vs. 350 cells/mm3 (OR 3.9 vs. 2000 cells/mm3 (OR 1.7 vs. 25 yielded the sensitivity of 46.7%, specificity of 79.1%, positive predictive value of 67.7%, and negative predictive value of 61.2% for prediction of pre-treatment HIV RNA

Informacja